Purpose Osteosarcoma is the most common childhood bone cancer. Interleukin-1 beta (IL-1B) is crucially involved in osteosarcoma carcinogenesis. Whether genetic polymorphisms of IL-1B also influence osteosarcoma risk is unknown. The aim of this study was to investigate the association between IL-1B gene polymorphisms and osteosarcoma risk in Chinese Han patients. Methods A hospital-based case-control study involving 120 osteosarcoma patients and 120 controls was conducted. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis was performed to detect three IL-1B gene polymorphisms (−31 T/C, −511 C/T and + 3954 C/T) in these patients. Conclusions This is the first study to provide evidence for an association of IL-1B gene polymorphisms with osteosarcoma risk.
Introduction
Osteosarcoma is the most commonly diagnosed primary malignancy of bone, particularly among children and adolescents, but there is a second incidence peak among individuals >60 years [1, 2] . Osteosarcoma is a complex, multistep and multifactorial process in which many factors are implicated [3] [4] [5] . Several research groups are investigating cancer stem cells and their potential to cause tumours [6, 7] . Bone dysplasias, Li-Fraumeni syndrome and Rothmund-Thomson syndrome are associated with increased risk of osteosarcoma [8, 3, 4, 6, 5] . Previous studies suggest a genetic predisposition for osteosarcoma [9] [10] [11] [12] [13] .
The interleukin-1 (IL-1) gene cluster on chromosome 2q contains three related genes within a 430-kilobase (kb) region, IL-1A, IL-1B and IL-1RN [14] . The IL-1B gene, encoding IL1beta cytokine, contains several single-nucleotide polymorphisms (SNPs). Three di-allelic polymorphisms in IL-1B have been reported, all representing C-T base transitions, at positions −511, −31 and +3954 base pairs (bp) from the transcriptional start site [14] . These polymorphisms have been associated with increased risk of developing a number of inflammatory diseases and cancer [15] [16] [17] [18] [19] [20] .
The IL-1B is crucially involved in osteosarcoma carcinogenesis [21] [22] [23] . Whether genetic polymorphisms of IL-1B also influence osteosarcoma risk is unknown. The aim of this study was to investigate the association between IL-1B gene polymorphisms and osteosarcoma risk in Chinese Han patients.
Materials and methods

Study participants
A hospital-based case-control study involving 120 osteosarcoma patients and 120 controls was conducted between January 2009 to January 2014 in the Union Hospital of Tongji Medical College and Cancer Hospital of Wuhan University (Wuhan, China). The healthy controls, who were free from any cancer and matched by gender and age, were recruited when they were attending a clinic for routine examination. These controls were genetically unrelated to the patients. Osteosarcoma patients were newly diagnosed and histopathologically confirmed independently by two gynaecologic pathologists. For the cases, clinical and pathological information was extracted, including Enneking stage (I-III), tumour location (extremities and other), histological type (osteoblastic, chondroblastic, fibroblastic and mixed), tumour metastasis and family history of cancer. The Chinese Han population was collected from the same geographic region. Written informed consents were obtained according to the Declaration of Helsinki from both groups. The Ethical Committee of the Union Hospital of Tongji Medical College and Cancer Hospital of Wuhan University approved the study protocols.
Genotyping
Genomic DNA was extracted from peripheral blood mononuclear cells of study participants using the QIAamp DNA blood minikit (QIAGEN Inc., Valencia, CA, USA). The IL-1B −31 T/C, −511 C/T and +3954 C/T gene polymorphisms were then determined using a polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. Based on the GenBank reference sequence, the PCR primers designed for IL-1B −31 T/C, −511 C/T and +3954 C/T were 5′-TCT TTT CCC CTT TCC TTT AAC T -3′ (forward) and 5′-GAG AGA CTC CCT TAG CAC CTA GT -3′ (reverse); 5′-CTG CAT ACC GTA TGT TCT CTG CC -3′ (forward) and 5′-GGA ATC TTC CCA CTTA CAG ATG G -3′ (reverse); 5′-GAC TTT GAC CGT ATA TGC TCA G -3′ (forward) and 5′-ATG GAC CAG ACA TCA CCA AGC -3′ (reverse), respectively. Reaction conditions were: ten minutes at 95°C, 40 cycles of 30 seconds at 72°C, 20 seconds at 95°C, 30 seconds at 59°C. PCR products were digested overnight with the appropriate restriction enzymes (New England Biolabs, Beverly, MA, USA), which were AluI for the −31 T/C, DdeI for the −511 C/T and NcoI and TaqI for the +3954 C/T polymorphisms. The digested PCR products were resolved on a 3 % agarose gel and stained with ethidium bromide for visualization under ultraviolet (UV) light. For quality control, the genotyping analysis was done blind as regards participants. The selected PCR-amplified DNA samples were also examined by DNA sequencing to confirm genotyping results.
Statistical analysis
The Statistical Analysis System software (Version 11; SAS Institute Inc., Cary, NC, USA) was used to perform all statistical analyses. Comparisons between groups were made using the x 2 test (nominal data) or Student's t test (interval data). Comparison of genotypes of IL-1B variants between cases and controls was evaluated using the chi-square test. Crude odds ratios (OR) and adjusted ORs for sex and age, with 95 % confidence interval (CI), were calculated by logistic regression analysis. The Hardy-Weinberg equilibrium was tested for goodness-of-fit chi-square test with one degree of freedom to compare the observed genotype frequencies among individuals with the expected genotype frequencies. P value < 0.05 was considered statistically significant.
Results
Participant characteristics
Clinicopathological characteristics in patients with osteosarcoma and in controls are presented in Table 1 . Cases and controls did not differ regarding gender (P=0.60) or age (P=0.81). Nine (7.5 %) cases Enneking stage I osteosarcoma, 56 (46.7 %) were stage II osteosarcoma and 55 (45.8 %) were stage III osteosarcoma. Tumour location of these cases were 91 (75.8 %) in extremities and 29 (24.2 %) other osteosarcoma. Histological types were 38 (31.6 %) osteoblastic osteosarcoma, 41 (34.2 %) were chondroblastic osteosarcoma, 15 (12.5 %) were fibroblastic osteosarcoma and 26 (21.7 %) were mixed osteosarcoma. Tumour metastasis were positive osteosarcoma in 55 (45.8 %) and negative osteosarcoma in 65 (54.2 %). Family history of cancer in these cases showed 11 (9.2 %) were positive and 109 (90.8 %) were negative.
IL-1B −31 T/C polymorphism and osteosarcoma
Patients with osteosarcoma had a significantly lower frequency of −31 CC genotype (OR =0.40, 95 % CI=0.17-0.92; P= 0.03) and −31 C allele (OR=0.67, 95 % CI=0.46-0.99; P= 0.04) than controls (Table 2) . When stratified by Enneking stage, tumour location, histological type, tumour metastasis of osteosarcoma and family history of cancer, no statistically significant results was found (Table 3) .
IL-1B −511 C/T polymorphism and osteosarcoma
Patients with osteosarcoma had a significantly lower frequency of −511 TT genotype (OR=0.40, 95 % CI=0.17-0.95; P= 0.04) than controls (Table 2) . When stratified by Enneking stage, tumour location, histological type, tumour metastasis of osteosarcoma and family history of cancer, no statistically significant results were found (Table 3) .
IL-1B +3954 C/T polymorphism and osteosarcoma
The +3954 C/T polymorphisms were not associated with a risk of osteosarcoma (Table 2) . When stratified by Enneking stage, tumour location, histological type, tumour metastasis of osteosarcoma and family history of cancer, no statistically significant results were found (Table 3) .
Discussion
There is increasing evidence of the association between genetic polymorphisms and risk of osteosarcoma. A case-control study found that polymorphisms of ITGA3 gene rs2230392 may affect incidence, metastasis and survival in patients with osteosarcoma and have prognostic value [24] . Another study provided the first evidence for the association between collagen type I alpha-1 polymorphism and osteosarcoma risk in Chinese [9] . A case-control study suggested that IL-12 gene polymorphisms were associated with the risk of osteosarcoma [25] . A meta-analysis of seven studies suggested that the rs231775 polymorphism of cytotoxic Tlymphocyte antigen-4 may play an important role in osteosarcoma carcinogenesis [26, 13, 27] . A hospital-based casecontrol study suggested that bisphenol A exposure interacts with the −22 G/C polymorphism of the lysyl oxidase gene to increase the risk of osteosarcoma [11] . A case-control study suggested that genotype CC in PIK3CA locus rs7646409 may increase the risk of osteosarcoma in the Chinese population [10] . A case-control study suggested that MDM2 genetic variants are potentially related to osteosarcoma susceptibility in Chinese Han population [28] . A case-control study suggested that the +1057G/A polymorphism of the CD86 gene was associated with increased susceptibility to osteosarcoma [29] . Another study concluded that Int7G24A was a polymorphism of TGFBR1 that is associated with the susceptibility and distant metastasis of osteosarcoma [30] . A case-control study suggested that PON1 192 wild-type genotypes may be associated with a risk of developing osteosarcoma [31] . A case-control study suggested an association between Fas exon 3 A>G polymorphism and osteosarcoma risk [32] .
The association between IL-1B gene polymorphisms and other cancer types was much studied [33] . A case-control study demonstrated that genotype CC or CT of IL-1B −31, TT or CT of IL-1B −511 increased the risk of gastric cancer in this Chinese population, and the risk was further enhanced by Helicobacter pylori [34] . A meta-analysis of 39 studies, which compared 6,863 gastric cancer cases and 8,434 controls, suggested that IL-1B −511 genetic polymorphisms were associated with an increased risk of developing gastric cancer [35] . A case-control study suggested that IL-1B −511 C/T gene polymorphisms were associated with cervical cancer risk in Egyptian women [36] . Another study provided evidence of an association between IL-1B +3953 polymorphism and risk of cervical cancer [37] . A case-control study demonstrated that the IL-1B −31 T allele was positively associated with a risk for non-small-cell lung cancer (NSCLC), and the carriers of IL-1B −31 T/T or −511C/C would have a higher risk of developing NSCLC if they drank alcohol or smoked heavily [38] . A casecontrol study demonstrated that IL-1B gene polymorphisms influenced survival rates in patients with pancreatic cancer [39] . Some shortcomings of this study should be noted. Firstly, although our study suggested statistically significant interactions between IL-1B gene polymorphisms and osteosarcoma risk, more biological background data are needed to explain our results. Secondly, this study only considers a Chinese population, which may limit the application of these findings to other ethnic populations. Thirdly, this is a hospital-based case -control study, so selection bias may not be avoidable, and participants may not be representative of the general population. Finally, findings might involve gene-toenvironment interactions, which are not explored here.
In conclusion, to the best of our knowledge, this is the first study to provide evidence for an association between IL-1B gene polymorphisms and osteosarcoma risk. Our study suggests that patients with osteosarcoma have a significantly lower frequency of IL-1B −31 CC genotype, IL-1B −511 TT genotype and IL-1B −31 C allele than controls. We also found that IL-1B +3954 C/T gene polymorphisms are not associated with a risk of osteosarcoma. However, it is highly desirable that our findings are validated through replication in other case-control series.
